Trade names Lotemax ATC code S01BA14 (WHO) Molar mass 466.951 g/mol | Routes ofadministration Eye drops Legal status US: ℞-only CAS ID 82034-46-6 Protein binding 95% | |
 | ||
AHFS/Drugs.com Micromedex Detailed Consumer Information Pregnancycategory US: C (Risk not ruled out) | ||
How to pronounce loteprednol lotemax memorizing pharmacology flashcard
Loteprednol (as the ester loteprednol etabonate) is a corticosteroid used to treat inflammations of the eye. It is marketed by Bausch and Lomb as Lotemax and Loterex.
Contents
- How to pronounce loteprednol lotemax memorizing pharmacology flashcard
- Medical vocabulary what does loteprednol etabonate mean
- Medical uses
- Contraindications
- Adverse effects
- Interactions
- Pharmacokinetics
- Retrometabolic drug design
- Chemistry
- References
Medical vocabulary what does loteprednol etabonate mean
Medical uses
Applications for this drug include the reduction of inflammation after eye surgery, seasonal allergic conjunctivitis, uveitis, as well as chronic forms of keratitis (e.g. adenoviral and Thygeson's keratitis), vernal keratoconjunctivitis, pingueculitis, and episcleritis.
Contraindications
As corticosteroids are immunosuppressive, loteprednol is contraindicated in patients with viral, fungal or mycobacterial infections of the eye.
Adverse effects
Common adverse effects include foreign body sensation in the eye, dry eye and epiphora (overflow of tears), chemosis (swelling of the conjunctiva), headache, and itching. Increased intraocular pressure (IOP), a side effect typical of corticosteroids, occurs in about 2% of patients (compared to 7% under prednisolone acetate, an older anti-inflammatory agent which is prescribed after eye surgery, and 0.5% under placebo). Loteprednol is also far less likely to cause elevated IOP compared to dexamethasone.
Interactions
The effect of drugs lowering intraocular pressure may be reduced. Loteprednol is not detectable in the bloodstream; so interactions with systemic drugs are highly unlikely.
Pharmacokinetics
Neither loteprednol etabonate nor its inactive metabolites Δ1-cortienic acid and Δ1-cortienic acid etabonate are detectable in the bloodstream, even after oral administration. A study with patients receiving loteprednol eye drops over 42 days showed no adrenal suppression, which would be a sign of the drug reaching the bloodstream to a clinically relevant extent.
Steroid receptor affinity was 4.3 times that of dexamethasone in animal studies.
Retrometabolic drug design
Loteprednol etabonate was developed using retrometabolic drug design. It is a so-called soft drug, meaning its structure was designed so that it is predictably metabolised to inactive substances. These metabolites, Δ1-cortienic acid and its etabonate, are derivatives of cortienic acid, itself an inactive metabolite of hydrocortisone.
Chemistry
Loteprednol etabonate is an ester of loteprednol with etabonate (ethyl carbonate), with a melting point between 220.5 °C (428.9 °F) and 223.5 °C (434.3 °F). Its solubility in water is 1:2,000,000. The ketone in the side chain of classical corticosteroids such as hydrocortisone is replaced by a cleavable ester, which accounts for the rapid inactivation. (This is not the same as the etabonate ester.)